| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-132 |
Sentence |
denotes |
The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project. |
| T1 |
0-132 |
Sentence |
denotes |
The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project. |
| T2 |
133-282 |
Sentence |
denotes |
Epistasis between interleukin-10 (IL10) and aromatase gene polymorphisms has previously been reported to modify the risk of Alzheimer's disease (AD). |
| T2 |
133-282 |
Sentence |
denotes |
Epistasis between interleukin-10 (IL10) and aromatase gene polymorphisms has previously been reported to modify the risk of Alzheimer's disease (AD). |
| T3 |
283-472 |
Sentence |
denotes |
However, although the main effects of aromatase variants suggest a sex-specific effect in AD, there has been insufficient power to detect sex-specific epistasis between these genes to date. |
| T3 |
283-472 |
Sentence |
denotes |
However, although the main effects of aromatase variants suggest a sex-specific effect in AD, there has been insufficient power to detect sex-specific epistasis between these genes to date. |
| T4 |
473-560 |
Sentence |
denotes |
Here we used the cohort of 1757 AD patients and 6294 controls in the Epistasis Project. |
| T4 |
473-560 |
Sentence |
denotes |
Here we used the cohort of 1757 AD patients and 6294 controls in the Epistasis Project. |
| T5 |
561-751 |
Sentence |
denotes |
We replicated the previously reported main effects of aromatase polymorphisms in AD risk in women, for example, adjusted odds ratio of disease for rs1065778 GG=1.22 (95% confidence interval: |
| T5 |
561-751 |
Sentence |
denotes |
We replicated the previously reported main effects of aromatase polymorphisms in AD risk in women, for example, adjusted odds ratio of disease for rs1065778 GG=1.22 (95% confidence interval: |
| T6 |
752-771 |
Sentence |
denotes |
1.01-1.48, P=0.03). |
| T6 |
752-771 |
Sentence |
denotes |
1.01-1.48, P=0.03). |
| T7 |
772-949 |
Sentence |
denotes |
We also confirmed a reported epistatic interaction between IL10 rs1800896 and aromatase (CYP19A1) rs1062033, again only in women: adjusted synergy factor=1.94 (1.16-3.25, 0.01). |
| T7 |
772-949 |
Sentence |
denotes |
We also confirmed a reported epistatic interaction between IL10 rs1800896 and aromatase (CYP19A1) rs1062033, again only in women: adjusted synergy factor=1.94 (1.16-3.25, 0.01). |
| T8 |
950-1098 |
Sentence |
denotes |
Aromatase, a rate-limiting enzyme in the synthesis of estrogens, is expressed in AD-relevant brain regions ,and is downregulated during the disease. |
| T8 |
950-1098 |
Sentence |
denotes |
Aromatase, a rate-limiting enzyme in the synthesis of estrogens, is expressed in AD-relevant brain regions ,and is downregulated during the disease. |
| T9 |
1099-1138 |
Sentence |
denotes |
IL-10 is an anti-inflammatory cytokine. |
| T9 |
1099-1138 |
Sentence |
denotes |
IL-10 is an anti-inflammatory cytokine. |
| T10 |
1139-1295 |
Sentence |
denotes |
Given that estrogens have neuroprotective and anti-inflammatory activities and regulate microglial cytokine production, epistasis is biologically plausible. |
| T10 |
1139-1295 |
Sentence |
denotes |
Given that estrogens have neuroprotective and anti-inflammatory activities and regulate microglial cytokine production, epistasis is biologically plausible. |
| T11 |
1296-1478 |
Sentence |
denotes |
Diminishing serum estrogen in postmenopausal women, coupled with suboptimal brain estrogen synthesis, may contribute to the inflammatory state, that is a pathological hallmark of AD. |
| T11 |
1296-1478 |
Sentence |
denotes |
Diminishing serum estrogen in postmenopausal women, coupled with suboptimal brain estrogen synthesis, may contribute to the inflammatory state, that is a pathological hallmark of AD. |